The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Major Adverse Cardiac Events (MACE)
Timeframe: up to 1 year
Composite of cardiovascular death, recurrent myocardial infarction, stroke, or unplanned ischemia driven revascularization
Timeframe: through study completion, an estimated average of 3 years
Total composite events of cardiovascular death or new or worsening heart failure (co-primary 1)
Timeframe: through study completion, an estimated average of 3 years
Composite of cardiovascular death, new or worsening heart failure, recurrent myocardial infarction, or stroke (co-primary 2)
Timeframe: through study completion, an estimated average of 3 years